CymaBay Therapeutics ( NASDAQ:CBAY – Free Report ) had its price target increased by Raymond James from $17.00 to $33.00 in a research note issued to investors on Thursday, MarketBeat reports. They currently have a strong-buy rating on the biopharmaceutical company's stock. Other research analysts have also recently issued research reports about the stock. B. Riley upped their target price on shares of CymaBay Therapeutics from $8.00 to $16.00 and gave the stock a buy rating in a research report on Monday, July 31st.

https://www.dailypolitical.com/2023/09/10/cymabay-therapeutics-nasdaqcbay-price-target-raised-to-33-00.html

#dailypolitical